AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Advanced Management of Autoimmune Connective Tissue Diseases

Description

The presentation covered advanced management strategies for autoimmune connective tissue diseases, emphasizing systemic sclerosis, eosinophilic fasciitis, and lupus through a series of patient cases. In a case of systemic sclerosis, a 68-year-old woman experienced severe skin tightening and other symptoms; various treatment options were discussed, including methotrexate, mycophenolate mofetil, rituximab, and JAK inhibitors like upatacitinib, demonstrating varying success. A second case involved a 56-year-old female diagnosed with eosinophilic fasciitis, who showed limited improvement despite treatments like methotrexate and anti-IL-5 therapies, with IVIG considered based on anecdotal evidence. The last case highlighted a 17-year-old male with lupus, treated with vority of medications including rituximab and anafrolumab, showing significant response in managing cutaneous symptoms. Overall, the discussions illustrated the complexity of treatment decisions based on specific patient responses and evolving medication approvals, while underscoring the need for ongoing clinical trials and personalized treatment approaches.

View more

Conclusions

  • Advanced management of systemic sclerosis shows significant potential with the use of rituximab and JAK inhibitors, particularly in improving skin and lung function.
  • Rituximab is effective in reducing skin thickening in systemic sclerosis and also stabilizes lung function based on existing studies.
  • IVIG provides anecdotal and limited evidence of efficacy primarily for skin involvement, without consistent benefits observed for lung function.
  • Upadacitinib significantly improves skin thickening and shows a potential to stabilize lung disease in systemic sclerosis patients.
  • In eosinophilic fasciitis, IVIG and rituximab have shown partial responses in refractory cases but benefit remains anecdotal and more investigation is warranted.
  • Mepolizumab has been added in cases of eosinophilic fasciitis, showing promise, but further studies are needed to establish efficacy.
  • In cutaneous lupus, belimumab demonstrates clinical efficacy leading to significant improvements, although more dedicated studies focusing solely on cutaneous lupus are needed.
  • Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O; EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015 Jun;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522. Epub 2014 Jan 17. PMID: 24442885.
  • Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Asano Y, Okiyama N, Kodera M, Hasegawa M, Sato S. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jul;3(7):e489-e497. doi: 10.1016/S2665-9913(21)00107-7. Epub 2021 May 26. PMID: 38279402.
  • Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clinical and experimental rheumatology. 2013;31(2 Suppl 76):151-156. Accessed March 26, 2022. https://search-ebscohost-com.treadwell.idm.oclc.org/login.aspx?direct=true&db=mdc&AN=23910617&site=eds-live&scope=site
  • Poelman CL, Hummers LK, Wigley FM, Anderson C, Boin F, Shah AA. Intravenous Immunoglobulin May Be an Effective Therapy for Refractory, Active Diffuse Cutaneous Systemic Sclerosis. Journal of Rheumatology. 2015;42(2):236-242. Accessed March 26, 2022. https://search-ebscohost-com.treadwell.idm.oclc.org/login.aspx?direct=true&db=edo&AN=101066520&site=eds-live&scope=site
  • Benucci M, et al. JAK inhibitors and autoimmune rheumatic diseases, Autoimmunity Reviews. Volume 22, Issue 4, 2023, 103276, ISSN 1568-9972, https://doi.org/10.1016/j.autrev.2023.103276.
  • Moriana C, Moulinet T, Jassaud R, Decker P. JAK inhibitors and systemic sclerosis: A systematic review of the literature. Autoimmun Rev. 2022 Oct;21(10):103168. doi: 10.1016/j.autrev.2022.103168.
  • Lucero E, Pons-Estel B, Rivero M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 2020;8(10):963-974. doi:10.1016/S2213-2600(20)30318-0
  • llanore et al. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607. doi: 10.1136/annrheumdis-2020-218447. Epub 2020 Sep 22. PMID: 32963047; PMCID: PMC7677494.
  • Spiera R et al. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis Rheumatol. 2020 Aug;72(8):1350-1360. doi: 10.1002/art.41294. Epub 2020 Jul 17. PMID: 32336038; PMCID: PMC7497006.
  • Kneeland, R ., Montes, D ., Endo, J ., Shields, B ., Bartels, C.M. and Garg, S. (2023), Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and Meta-Analysis. Arthritis Care Res, 75: 1838-1848. https://doi-org.ezp-prod1.hul.harvard.edu/10.1002/acr.25058
  • Furie RA, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022 Jan;81(1):100-107. doi: 10.1136/annrheumdis-2021-220920. Epub 2021 Oct 6. PMID: 34615636; PMCID: PMC8762029.
  • Furie RA et al; REGENCY Trial Investigators. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2410965. Epub ahead of print. PMID: 39927615.
  • Vital EM, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(6):1586-1591.
  • Quelhas da Costa R, et al. Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus. JAMA Dermatol. 2018;154(12):1432-1440. doi:10.1001/jamadermatol.2018.3793.